The aim of this study is to assess the dermatological tolerance of the investigational product "Crème visage Product code: RV4983A / Formula code: LA3365" after 95 days for subjects post peeling and LASER and 176 days for subjects post injections of once daily use at the evening on the half face, under normal conditions of use, on 66 subjects. This study will be conducted as a national, monocentric, open trial. Planning of the visits: * Visit 1: Inclusion (Day 1) - The subjects undergo their procedure (peeling, LASER or injections). * Home application of the associated product 1 period: Day 1 to Day 7 * Visit 2: intermediate visit (Day 8) subjects received investigational product and associated product 2; * Visit 3, 4, and 5: Intermediate visit (Day 37, Day 66 and Day 95\*), \*the final visit for the subjects post peeling and LASER * Visit 6\*\*: End of study (Day 176), \*\* for subjects post injections
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Assessment of dermatological physical signs by the investigator
Timeframe: At the Visit 2 (Day 8, before and immediately after investigational product application: 10 to 30 minutes) and at the Day 37, Day 66, Day 95 and Day 176 (for post-injections subjects) visit.
Assessment of dermatological functional signs by the subject
Timeframe: At the Visit 2 (Day 8, before and immediately after investigational product application: 10 to 30 minutes) and at the Day 37, Day 66, Day 95 and Day 176 (for post-injections subjects) visit
Recording of reactions
Timeframe: During the entire course of the study (from Day 1 to Day 95 or Day 176)
Global tolerance assessment by the investigator
Timeframe: At the end of study (Day 176)